Clinical Trial Search

Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Tirzepatide From Time Zero to Infinity (AUC0toinf) — 101000; 104000 Nanogram*hour per…

Primary: Number of Patients With Treatment-Emergent Adverse Events (TEAE) — 7; 6; 5 Participants

Primary: Frequency of Grade 2 or Higher Adverse Events (AEs) — 1; 2; 0 Participants

Primary: Count of Treatment Emergent Adverse Events (TEAEs) — 2; 2; 2; 1 Participants

Primary: Average Tenofovir Diphosphate Concentrations in Mixed Rectal Cells During the Early (Low Estradiol) Follicular Phases of the Menstrual Cycle. — 406.14 fmol/million cells

Primary: Satisfaction With Assigned Treatment — 0; 1; 17; 18 Participants — p=.999

Primary: Frequency and Severity of Solicited Local Events Post Dose 1 by Treatment Group for All Participants — 15; 22; 10; 18 Participants

Primary: Part 1: Number of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs) for PvP001 and PvP002 — 0; 0; 0; 0 Participants

Primary: (-/+)-M1, AUC(0-32) and AUC(Inf) — 136.0; 274.9; 408.8; 450.7 ng*hr/mL

Primary: Number of Participants With Treatment-emergent Adverse Events — 7; 6; 6; 6 Participants

Primary: Change From Baseline up to 12 Hours Postdose in QT Interval Corrected for Heart Rate (QTc) — -7.1; -6.66; -7.7; -4.7 milliseconds

Primary: Number of Participants Experiencing Dose Limiting Toxicity (DLT) Events — 0; 0; 0 Participants

Primary: Gastric pH >4 Holding Time Ratio (HTR): Percentage of Time Gastric pH Was Above 4 Over a 24-hour Monitoring Period Following Study Drug Administration — 62.40; 22.61…

Primary: Safety: Number of Participants With Major Bleeding Events — 1 Participants

Primary: Number of Patients With Cycle 1 and 2 Dose Limiting Toxicities Attributable to Nanoparticle Albumin-bound Rapamycin — 1; 2; 1; 1 Participants